AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38206849 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall exercise intervention
Number of subjects: 44
Study 38206930 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (0.5‒2 mg) and Bupropion SR (150‒300 mg)
Number of subjects: 380
Study 38206930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 38207119 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical NK cells plus IL-2
Number of subjects: 6
Study 38207119 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical NK cells plus N-803
Number of subjects: 6
Study 38207172 — intervention group
Group type: EXPERIMENTAL
Intervention: PAVS and best practice advisory integrated into EHR
Number of subjects: 0
Study 38207172 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice advisory
Number of subjects: 0
Study 38207172 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring via Fitbit
Number of subjects: 0
Study 38207195 — intervention group
Group type: EXPERIMENTAL
Intervention: Big-step instruction
Number of subjects: 45
Study 38207195 — intervention group
Group type: COMPARATOR
Intervention: Heel strike instruction
Number of subjects: 45
Study 38207208 — intervention group
Group type: EXPERIMENTAL
Intervention: mini-hyper-CVD plus venetoclax (200 mg or 400 mg daily)
Number of subjects: 22
Study 38207208 — intervention group
Group type: EXPERIMENTAL
Intervention: mini-hyper-CVD plus venetoclax
Number of subjects: 22
Study 38207246 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with proactive symptom assessment (peer volunteer weekly phone calls)
Number of subjects: 60
Study 38207246 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 38207282 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome analysis of elite athletes with SCI
Number of subjects: 11
Study 38211393 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/day
Number of subjects: 22
Study 38211601 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral linezolid (600 mg once per day for 5 days)
Number of subjects: 59
Study 38211601 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular benzathine penicillin G (single dose of 2.4 million international units)
Number of subjects: 59
Study 38211601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 59
Study 38211604 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 72 μg once daily for 12 weeks
Number of subjects: 330
Study 38211604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 38211606 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtyping-based therapy (nab-paclitaxel 100 mg/m2 in 28-day cycles)
Number of subjects: 139
Study 38211606 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 139
Study 38211606 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtyping-based therapy
Number of subjects: 139
Study 38211606 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139
Study 38211660 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 97
Study 38211725 — intervention group
Group type: EXPERIMENTAL
Intervention: CoCM plus Written Exposure Therapy (CoCM+WET)
Number of subjects: 720
Study 38211725 — intervention group
Group type: COMPARATOR
Intervention: CoCM only
Number of subjects: 720
Study 38211725 — intervention group
Group type: EXPERIMENTAL
Intervention: CoCM+WET
Number of subjects: 720
Study 38211747 — intervention group
Group type: EXPERIMENTAL
Intervention: Meru Health Program (MHP), 12 weeks duration
Number of subjects: 100
Study 38211747 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 100
Study 38211934 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular, transcatheter, right-sided greater splanchnic nerve ablation (SAVM)
Number of subjects: 90
Study 38211934 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 90
Study 38212048 — intervention group
Group type: EXPERIMENTAL
Intervention: HoloLens-assisted thoracic epidural technique
Number of subjects: 83
Study 38212048 — intervention group
Group type: COMPARATOR
Intervention: Traditional thoracic epidural technique
Number of subjects: 83
Study 38212068 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Internal Radiation Therapy (SIRT)
Number of subjects: 0
Study 38212105 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene bag placed before cord clamping (BEFORE)
Number of subjects: 198
Study 38212105 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene bag placed after cord clamping (AFTER)
Number of subjects: 198
Study 38212104 — intervention group
Group type: EXPERIMENTAL
Intervention: CC+SI
Number of subjects: 218
Study 38212104 — intervention group
Group type: COMPARATOR
Intervention: 3:1 C:V
Number of subjects: 218
Study 38212127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of low-dose nivolumab (10 mg, every 2 weeks) plus intratumoral administration of 10 mg ipilimumab and 50 µg AS01
Number of subjects: 8
Study 38212160 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized 2-wk controlled diet designed to emulate their usual diet
Number of subjects: 153
Study 38212183 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid use at M12
Number of subjects: 2326
Study 38212183 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid use at M6
Number of subjects: 2326
Study 38212183 — intervention group
Group type: EXPERIMENTAL
Intervention: New opioid users
Number of subjects: 2326
Study 38212183 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and interference reported by M12 opioid users
Number of subjects: 2326
Study 38212183 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative opioid use
Number of subjects: 2326
Study 38212206 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world clinical practice (RWCP) therapy
Number of subjects: 24
Study 38212245 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI of ≥30 kg/m2)
Number of subjects: 2628
Study 38212245 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity (≥73.5 MET-hours per week)
Number of subjects: 2628
Study 38212245 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy smoking (>30 pack-years)
Number of subjects: 2628
Study 38212245 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep (<6 hours per day)
Number of subjects: 2628
Study 38212308 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous artificial intelligence diabetic eye exam at the point of care
Number of subjects: 164
Study 38212308 — intervention group
Group type: COMPARATOR
Intervention: Scripted eye care provider referral and education (Control)
Number of subjects: 164
Study 38212321 — intervention group
Group type: EXPERIMENTAL
Intervention: DHES0815A
Number of subjects: 0
Study 38212321 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of DHES0815A
Number of subjects: 0
Study 38212582 — intervention group
Group type: EXPERIMENTAL
Intervention: Semen BPA (sBPA) levels
Number of subjects: 75
Study 38212582 — intervention group
Group type: EXPERIMENTAL
Intervention: High semen BPA (sBPA) levels
Number of subjects: 75
Study 38212582 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood BPA (bBPA) levels
Number of subjects: 75
Study 38212582 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated blood BPA (bBPA) levels
Number of subjects: 75
Study 38212607 — intervention group
Group type: EXPERIMENTAL
Intervention: DLS-assisted junior ophthalmologist group (test group)
Number of subjects: 748
Study 38212607 — intervention group
Group type: COMPARATOR
Intervention: Junior ophthalmologist group (control group)
Number of subjects: 748
Study 38212607 — intervention group
Group type: EXPERIMENTAL
Intervention: DLS group
Number of subjects: 748
Study 38212696 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal anxiety (measured by GAD-7)
Number of subjects: 0
Study 38212696 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depression (measured by EPDS)
Number of subjects: 0
Study 38212769 — intervention group
Group type: EXPERIMENTAL
Intervention: DNTGF-βR armored CAR-T cell therapy
Number of subjects: 0
Study 38212804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sage intervention (12-session manualized intervention)
Number of subjects: 5
Study 38212815 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training with anodal tDCS (1-mA, 20 min)
Number of subjects: 46
Study 38212815 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training with sham stimulation
Number of subjects: 46
Study 38212823 — intervention group
Group type: EXPERIMENTAL
Intervention: Buteyko breathing technique (BBT)
Number of subjects: 30
Study 38212823 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy (UT) without BBT
Number of subjects: 30
Study 38212837 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning (ML) model called IDoser for FSH dosing
Number of subjects: 236
Study 38212837 — intervention group
Group type: COMPARATOR
Intervention: Standard practice FSH dosing determined by clinician
Number of subjects: 236
Study 38212847 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily yogurt consumption (5 oz) for 8 weeks
Number of subjects: 20
Study 38212847 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yogurt consumption)
Number of subjects: 20
Study 38212851 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional individually tailored intervention including Norwegian Psychomotor Physiotherapy (NPMP), cognitive behavioural therapy, and a rehabilitation plan
Number of subjects: 18
Study 38212850 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance-related features (IR)
Number of subjects: 117
Study 38212850 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher triglyceride (TG) and lower estimated insulin sensitivity (eIS)
Number of subjects: 117
Study 38212850 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated insulin sensitivity (eIS)
Number of subjects: 117
Study 38212853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training (CBMT) - 4-week, 8-session, tablet-delivered intervention
Number of subjects: 49
Study 38212853 — intervention group
Group type: COMPARATOR
Intervention: Sham attention control group
Number of subjects: 49
Study 38212888 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed suture
Number of subjects: 72
Study 38212888 — intervention group
Group type: COMPARATOR
Intervention: Nonbarbed suture
Number of subjects: 72
Study 38212888 — intervention group
Group type: EXPERIMENTAL
Intervention: Both suture types
Number of subjects: 72
Study 38213401 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telerehabilitation (tele-physical/occupational therapy)
Number of subjects: 15
Study 38213637 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir-lamivudine (DTG/3TC)
Number of subjects: 741
Study 38213637 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir alafenamide-based regimens (TBR)
Number of subjects: 741
Study 38213637 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 741
Study 38214149 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828)
Number of subjects: 0
Study 38214149 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38214170 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal nanoparticles
Number of subjects: 0
Study 38214170 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38214239 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use ≤7 days of index stroke
Number of subjects: 1423
Study 38214239 — intervention group
Group type: COMPARATOR
Intervention: Control (non-aspirin users)
Number of subjects: 1423
Study 38214256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus-eluting stent with shortened dual antiplatelet therapy (DAPT) for 1 month for stable angina or 1 to 3 months for acute coronary syndrome at investigator's discretion.
Number of subjects: 315
Study 38214257 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in LVFS (Left Ventricular Fractional Shortening)
Number of subjects: 794
Study 38214257 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in LVEDD (Left Ventricular End-Diastolic Dimension)
Number of subjects: 794
Study 38214257 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in LV end-diastolic posterior wall thickness
Number of subjects: 794
Study 38214257 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in LV end-diastolic posterior wall thickness:LVEDD ratio
Number of subjects: 794
Study 38214257 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality and transplantation outcomes
Number of subjects: 794
Study 38214479 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 0
Study 38214479 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38214539 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and Nutrition Group (ENG)
Number of subjects: 60
Study 38214539 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 60
Study 38214552 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TXA (2g) administered 2 hours before surgery and 4 hours after incision
Number of subjects: 228
Study 38214552 — intervention group
Group type: COMPARATOR
Intervention: Intravenous TXA (1g) administered 30 minutes before surgery and 4 hours after incision
Number of subjects: 228
Study 38214552 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TXA
Number of subjects: 228
Study 38214552 — intervention group
Group type: COMPARATOR
Intervention: Oral TXA and Intravenous TXA
Number of subjects: 228
Study 38214677 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Sinus Reducer (CSR)
Number of subjects: 0
Study 38214677 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 0
Study 38214710 — intervention group
Group type: EXPERIMENTAL
Intervention: Shatavari (26,500 mg/d fresh weight)
Number of subjects: 12
Study 38214710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 38214710 — intervention group
Group type: EXPERIMENTAL
Intervention: Shatavari
Number of subjects: 12
Study 38214733 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (provided 50-500 ms after perturbation)
Number of subjects: 12
Study 38214733 — intervention group
Group type: COMPARATOR
Intervention: No functional electrical stimulation
Number of subjects: 12
Study 38214733 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Number of subjects: 12
Study 38214795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysticlean™ 240 mg
Number of subjects: 160
Study 38214795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 38214917 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38214956 — intervention group
Group type: EXPERIMENTAL
Intervention: Chanjo Kwa Wakati (community-based digital health intervention)
Number of subjects: 1200
Study 38214956 — intervention group
Group type: COMPARATOR
Intervention: Delayed onset study arm (control group)
Number of subjects: 1200
Study 38214963 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosie chatbot treatment group
Number of subjects: 29
Study 38214963 — intervention group
Group type: COMPARATOR
Intervention: Control group (children's book)
Number of subjects: 29
Study 38215127 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopuncture therapy
Number of subjects: 41
Study 38215154 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver coaching NDBI
Number of subjects: 150
Study 38215154 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 38215205 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring Device A
Number of subjects: 0
Study 38215205 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring Device B
Number of subjects: 0
Study 38215275 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38215286 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg selenium as selenium-enriched yeast
Number of subjects: 412
Study 38215286 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 412
Study 38215351 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobar resection
Number of subjects: 0
Study 38215351 — intervention group
Group type: COMPARATOR
Intervention: Sublobar resection
Number of subjects: 0
Study 38215355 — intervention group
Group type: EXPERIMENTAL
Intervention: EV + P
Number of subjects: 149
Study 38215355 — intervention group
Group type: COMPARATOR
Intervention: EV mono
Number of subjects: 149
Study 38215395 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine plus rituximab (BR)
Number of subjects: 0
Study 38215395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 38215395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus rituximab (IR)
Number of subjects: 0
Study 38215438 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant polio:rhinovirus (lerapolturev)
Number of subjects: 19
Study 38215438 — intervention group
Group type: EXPERIMENTAL
Intervention: genetically modified oncolytic herpesvirus (G207)
Number of subjects: 19
Study 38215438 — intervention group
Group type: EXPERIMENTAL
Intervention: stereotactic catheter placement
Number of subjects: 19
Study 38215546 — intervention group
Group type: EXPERIMENTAL
Intervention: Avasopasem manganese (AVA)
Number of subjects: 2
Study 38215546 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 2
Study 38215598 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolabeled perfusion
Number of subjects: 0
Study 38215598 — intervention group
Group type: EXPERIMENTAL
Intervention: Water evaluation
Number of subjects: 0
Study 38215770 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalation to narrower-spectrum antibiotics (ampicillin, trimethoprim-sulfamethoxazole, cefuroxime, cefotaxime, ceftriaxone, amoxicillin-clavulanic acid, ciprofloxacin, or ertapenem)
Number of subjects: 344
Study 38215770 — intervention group
Group type: COMPARATOR
Intervention: Continue with empiric antipseudomonal β-lactam
Number of subjects: 344
Study 38215770 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalation group
Number of subjects: 344
Study 38215770 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 344
Study 38215808 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-DED (Artificial intelligence-adjudicated dispersion extent and distribution)
Number of subjects: 78
Study 38215876 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational Cohort (OBS)
Number of subjects: 2250
Study 38215876 — intervention group
Group type: COMPARATOR
Intervention: Randomized Clinical Trial (RCT)
Number of subjects: 2250
Study 38215886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone monoester
Number of subjects: 36
Study 38215886 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (10 g)
Number of subjects: 36
Study 38215886 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-ingestion of ketone monoester and whey protein
Number of subjects: 36
Study 38215932 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Number of subjects: 8256
Study 38215932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8256
Study 38215973 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) added to furosemide
Number of subjects: 230
Study 38215973 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to furosemide
Number of subjects: 230
Study 38216022 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab responders
Number of subjects: 1515
Study 38216022 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab nonresponders
Number of subjects: 1515
Study 38216183 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimise longitudinal cohort and qualitative interviews
Number of subjects: 1000
Study 38216183 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly quantitative surveys and daily diaries
Number of subjects: 1000
Study 38216183 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews at key time points
Number of subjects: 1000
Study 38216183 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement groups
Number of subjects: 1000
Study 38216189 — intervention group
Group type: EXPERIMENTAL
Intervention: AF screening enrichment using a risk prediction model (RPM) followed by 14 days of a continuous ECG patch
Number of subjects: 740
Study 38216189 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 740
Study 38216189 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups enriched by the RPM
Number of subjects: 740
Study 38216189 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups without invitation to 14 days of continuous ECG recording
Number of subjects: 740
Study 38216189 — intervention group
Group type: EXPERIMENTAL
Intervention: All four groups
Number of subjects: 740
Study 38216192 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralised trial models
Number of subjects: 0
Study 38216192 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrification of sponsor vehicle fleets
Number of subjects: 0
Study 38216198 — intervention group
Group type: EXPERIMENTAL
Intervention: Interruptive alert for oral fluid restriction in patients treated with intravenous furosemide
Number of subjects: 0
Study 38216198 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38216200 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (1650 mg daily)
Number of subjects: 200
Study 38216200 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 200
Study 38216290 — intervention group
Group type: EXPERIMENTAL
Intervention: RAID questionnaire
Number of subjects: 248
Study 38216290 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient global assessment
Number of subjects: 248
Study 38216290 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Activity Score (DAS)
Number of subjects: 248
Study 38216290 — intervention group
Group type: EXPERIMENTAL
Intervention: C reactive protein (CRP)
Number of subjects: 248